- ISIN
- US5588681057
- CUSIP
- 558868105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 6, 2007
Highlights
- Market Cap
- $10.77B
- Enterprise Value
- $10.83B
- EPS (TTM)
- -$12.61
- Total Revenue (TTM)
- $1.28B
- Gross Profit (TTM)
- $1.17B
- EBITDA (TTM)
- -$298.76M
- Year Range
- $299.17 - $615.00
- Target Price
- $634.40
- ROA (TTM)
- -26.12%
- ROE (TTM)
- -62.07%
- Avg. Volume (1M)
- 365K
- Avg. Volume Value (1M)
- $192.42M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
MDGL Performance Chart
Madrigal Pharmaceuticals, Inc. (MDGL) is down 19.8% since the beginning of the year. At $467 per share, MDGL is trading 24.0% below its 52-week high of $615. Investors who bought $1,000 worth of MDGL shares 5 years ago would now be looking at an investment worth $5,351.
Loading charts...
Compare this symbol against anything
Returns By Period
Madrigal Pharmaceuticals, Inc. (MDGL) has returned -19.75% so far this year and 54.65% over the past 12 months. Looking at the last ten years, MDGL has achieved an annualized return of 52.15%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
Madrigal Pharmaceuticals, Inc.
- 1D
- -5.23%
- 1M
- -11.51%
- 6M
- -4.49%
- YTD
- -19.75%
- 1Y
- 54.65%
- 3Y*
- 32.19%
- 5Y*
- 39.86%
- 10Y*
- 52.15%
- ALL TIME*
- 1.50%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
MDGL Monthly Returns History
Based on dividend-adjusted daily data since Feb 6, 2007, MDGL's average daily return is +0.17%, while the average monthly return is +3.67%. At this rate, an investment would double in approximately 1.6 years.
Historically, 47% of months were positive and 53% were negative. The best month was Dec 2022 with a return of +314.0%, while the worst month was Feb 2009 at -84.6%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.
On a daily basis, MDGL closed higher 48% of trading days. The best single day was Dec 19, 2022 with a return of +268.1%, while the worst single day was Feb 27, 2009 at -78.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -15.98% | -11.71% | 21.17% | -1.16% | -3.89% | 7.98% | -12.97% | -19.75% | |||||
| 2025 | 8.50% | 1.93% | -2.94% | 0.81% | -17.56% | 9.95% | -0.04% | 44.74% | 4.75% | -8.67% | 42.51% | -2.45% | 88.72% |
| 2024 | -6.34% | 8.99% | 13.06% | -23.60% | 15.75% | 18.63% | 1.61% | -13.18% | -14.13% | 22.20% | 26.55% | -5.98% | 33.36% |
| 2023 | -0.69% | -5.98% | -10.61% | 28.79% | -10.77% | -17.03% | -11.13% | -12.32% | -18.87% | -10.04% | 54.74% | 13.81% | -20.28% |
| 2022 | -32.05% | 61.25% | 5.68% | -28.66% | -5.16% | 7.82% | -12.24% | 14.80% | -9.89% | 8.97% | -1.00% | 313.99% | 242.52% |
| 2021 | 6.83% | 2.05% | -3.48% | 16.35% | -17.49% | -13.26% | -10.36% | -5.23% | -3.58% | -2.56% | 6.38% | 2.45% | -23.77% |
Benchmark Metrics
Madrigal Pharmaceuticals, Inc. has an annualized alpha of 38.28%, beta of 1.02, and R2 of 0.04 versus S&P 500 Index. Calculated based on daily prices since February 06, 2007.
- This stock participated in 128.30% of S&P 500 Index downside but only 98.84% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.04 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 38.28%
- Beta
- 1.02
- R²
- 0.04
- Upside Capture
- 98.84%
- Downside Capture
- 128.30%
Return for Risk
Risk / Return Rank
MDGL ranks 78 for risk / return — above 78% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| MDGL | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.19 | ||
| Sortino ratioReturn per unit of downside risk | -0.07 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.25 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 1.86 | 2.00 | -0.14 |
| Martin ratioReturn relative to average drawdown | 3.94 | 8.49 | -4.55 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Madrigal Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Madrigal Pharmaceuticals, Inc. was 98.40%, occurring on Feb 11, 2016. Recovery took 2396 trading sessions.
The current Madrigal Pharmaceuticals, Inc. drawdown is 22.48%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.40%Feb 2016 | 3y 13d | 9y 6mo | 12y 6moJan 2013 - Aug 2025 | — |
-87.64%Feb 2009 | 1y 4mo | 3y 11mo | 5y 3moOct 2007 - Jan 2013 | Financial crisis2007–2009 |
-51.43%Aug 2007 | 2mo 20d | 1mo 11d | 4mo 1dJun 2007 - Oct 2007 | — |
-29.36%Mar 2026 | 2mo 10d | — | 7mo 12dDec 2025 - now | — |
-20.10%Apr 2007 | 2mo 3d | 1mo 25d | 3mo 28dFeb 2007 - Jun 2007 | — |
Drawdown Indicators
| MDGL | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.40% | -56.78% | -41.62% |
Max Drawdown (1Y)Largest decline over 1 year | -29.36% | -9.10% | -20.26% |
Max Drawdown (3Y)Largest decline over 3 years | -38.75% | -18.90% | -19.85% |
Max Drawdown (5Y)Largest decline over 5 years | -61.41% | -25.43% | -35.98% |
Max Drawdown (10Y)Largest decline over 10 years | -82.19% | -33.92% | -48.27% |
Current DrawdownCurrent decline from peak | -22.48% | -1.58% | -20.90% |
Average DrawdownAverage peak-to-trough decline | -58.21% | -10.70% | -47.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.86% | 2.14% | +11.72% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Madrigal Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Madrigal Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for MDGL relative to other companies in the Biotechnology industry. Currently, MDGL has a P/S ratio of 9.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for MDGL in comparison with other companies in the Biotechnology industry. Currently, MDGL has a P/B value of 26.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with MDGL
Add Madrigal Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with MDGL